Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects

MLA

Shen Z, et al. “Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects.” Drug Design, Development and Therapy, vol. ume 11, July 2017, pp. 2077–86. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1e3e8ebc8c2c416ba280648bce2920eb&authtype=sso&custid=ns315887.

APA

Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, & Hall JW. (2017). Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Design, Development and Therapy, ume 11, 2077–2086.

Chicago

Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, and Hall JW. 2017. “Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects.” Drug Design, Development and Therapy ume 11 (July): 2077–86. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1e3e8ebc8c2c416ba280648bce2920eb&authtype=sso&custid=ns315887.